{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:38Z","timestamp":1788416018143,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) affects 40\u201350% of recipients and remains the leading cause of posttransplant mortality; median overall survival is approximately 5 months and 1-year survival is below 20%. Conventional salvage\u2014chemotherapy, immunosuppression withdrawal, donor lymphocyte infusion (DLI), hypomethylating agents, targeted agents, and second transplantation\u2014benefits a minority and has improved only incrementally over two decades. Relapse in this setting reflects leukemia that has survived an engrafted allogeneic immune system. Documented escape mechanisms include genomic loss of the mismatched human leukocyte antigen (HLA) haplotype, epigenetic downregulation of class II HLA molecules, checkpoint ligand upregulation, microenvironmental suppression, and clonal evolution\u2014each calling for targeted redirection of the graft-versus-leukemia (GVL) response rather than further nonspecific cytotoxicity. We propose a GVL Failure Framework that organizes posttransplant relapse into three biologically defined categories of immune escape, aligns matched cellular therapies with each, and overlays a separate clinical transplant-eligibility axis that sets the therapeutic goal. Several cellular strategies have matured: autologous and donor-derived chimeric antigen receptor T (CAR-T) cells targeting CD33, CD123, C-type lectin-like molecule 1 (CLL-1)\/CD371, and CD117; armored CAR-T products secreting interleukin-18; CD83-directed CAR-T cells targeting blasts and alloreactive T cells simultaneously; HLA-DRB1-directed CAR-T and chimeric antigen receptor natural killer (CAR-NK) cells exploiting donor-recipient mismatch for leukemia specificity; and off-the-shelf CAR-NK platforms reprogramming innate rather than adaptive allogeneic immunity. We integrate the mechanistic rationale and early clinical evidence for each approach, propose a four-pathway treatment algorithm built around relapse-clone HLA typing before DLI, and outline the gaps that must close before cellular therapy enters standard practice.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1910630","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:00Z","timestamp":1788412980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Naif I.","family":"AlJohani","sequence":"first","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam","family":"Almasari","sequence":"additional","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayed","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Shihata","sequence":"additional","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyam","family":"Usman","sequence":"additional","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassim","family":"Albeirouti","sequence":"additional","affiliation":[{"name":"Oncology Department, King Faisal Specialist Hospital and Research Centre","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812207","article-title":"Treatment of AML relapse after allo-HCT","volume":"11","author":"Webster","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3134","article-title":"Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years","volume":"26","author":"Bazarbachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254284","article-title":"Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation","volume":"115","author":"Villalobos","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02622-1","article-title":"HLA loss-mediated immune escape of acute leukemias in pediatric patients post haploidentical transplantation","volume":"60","author":"Arnold","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00113","article-title":"Donor selection and human leukocyte antigen loss leukemia relapse after hematopoietic cell transplantation","author":"Fleischhauer","year":"2026","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00207","article-title":"Epigenetic therapies for acute myeloid leukemia and their immune-related effects","volume":"7","author":"Gambacorta","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb8969","article-title":"Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans","volume":"12","author":"Uhl","year":"2020","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-026-02813-4","article-title":"Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation","volume":"61","author":"Maas-Bauer","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood-2024-203496","article-title":"Azacitidine and venetoclax as a salvage therapy for relapse after allogeneic transplantation for acute myeloid leukemia: a multicentric study from French AURAML group","volume":"144","author":"Tavernier","year":"2024","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation: a retrospective multicenter trial","volume":"100","author":"Amit","year":"2021","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/jco.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3 (MORPHO)","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/jco.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-025-00651-6","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.17426","article-title":"Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia","volume":"193","author":"Kharfan-Dabaja","year":"2021","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/blood-2024-207659","article-title":"The safety and efficacy of CD33 CAR-T therapy for R\/R AML after HSCT","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-025-00651-6","article-title":"Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031053","article-title":"A phase 1\/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed\/refractory AML after allogeneic HCT","volume":"147","author":"Mushtaq","year":"2026","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1182\/blood-2023-180990","article-title":"Phase 1\/2 study of donor-derived anti-CD33 chimeric antigen receptor expressing T cells (VCAR33) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B32","article-title":"First-in-class switchable allogeneic CAR-T therapy for CD123+ AML: results from the phase Ia RevSTAR-123 (AVC-201-01) study [abstract LBA5007","author":"Wermke","year":"2026"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04362-1","article-title":"CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1\/2 trial","volume":"32","author":"DiPersio","year":"2026","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-025-00934-1","article-title":"CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant","volume":"6","author":"Ikeda","year":"2025","journal-title":"Nat Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-026-04203-4","article-title":"Recent advances in CAR T and CAR NK cell therapy for AML","author":"Suga","year":"2026","journal-title":"Int J Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/jci135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","volume":"130","author":"Shrestha","year":"2020","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2837","article-title":"Human effectors of acute and chronic GVHD overexpress CD83 and predict mortality","volume":"29","author":"Holtan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B39","unstructured":"A Phase 1 Clinical Trial of CD83-Directed Chimeric Antigen Receptor T Cells in Relapsed or Refractory Acute Myeloid Leukemia. Clinicaltrials.Gov Identifier NCT06871410\n          \n          2026"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","article-title":"CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells","volume":"15","author":"Bexte","year":"2024","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024105","article-title":"HA-1\u2013targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1910630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:23:01Z","timestamp":1788412981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1910630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1910630"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1910630","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1910630"}}